Dr. Luai Samir Al Rabadi, MD

Dr. Al Rabadi practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Al Rabadi's NPI, 1659637452, was assigned on April 5, 2012. Dr. Al Rabadi graduated from Royal College of Surgeons Ireland in 2012. Dr. Al Rabadi holds California license A133367.

Dr. Al Rabadi's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Al Rabadi's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. Dr. Al Rabadi is also affiliated with MarinHealth Medical Center. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Al Rabadi to 4 more medical groups, 2 group practices and clinics and 1 dialysis center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Al Rabadi practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Al Rabadi's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Al Rabadi is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Al Rabadi's licenses on file in 3 states: California, Oregon and Ohio.

Dmand AI lists chronic anemia, deep vein thrombosis (DVT), purpura and thrombocytopenia and vitamin b deficiency among the conditions Dr. Al Rabadi treats.

CMS data shows 316 Medicare services from Dr. Al Rabadi across 8 procedure codes in 2024, for 129 Medicare patients. Medicare paid $24,180 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 129 Medicare patients who saw Dr. Al Rabadi in 2024. The largest group is 65 to 74, with 54 patients. 71% of them have high blood pressure, and 61% have high cholesterol. 62% are also on Medicaid. Their average risk score is 2.60, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Al Rabadi's median patient age at 69, with 45% women.

In 2024, Dr. Al Rabadi wrote 306 Medicare Part D claims for 56 patients. 69% of them were for generic drugs. CMS names the drug for 197 of them, across 12 drugs with 11 or more claims each, at $51,429 in total drug cost. In 2023, CMS named 248 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Al Rabadi for performance year 2024, reported as part of a group. Dr. Al Rabadi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Al Rabadi as offering telehealth.

Dmand AI links 5 papers to Dr. Al Rabadi, published from 2016 to 2021. 2020 was the busiest year, with 2. The most frequent topics are Breast Neoplasms and Receptor, ErbB-2. Dr. Al Rabadi's most frequent co-authors are Zahi Ibrahim Mitri, MD, Tomasz M. Beer, MD and Charles David Blanke, MD.

Dr. Al Rabadi graduated from Royal College of Surgeons Ireland in 2012.

Dr. Al Rabadi is in network with 9 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.